

Contents lists available at ScienceDirect

Data in brief





Data Article

Primary mitochondrial disease in the US: Data from patients and physicians' perspective on health care delivery



Amel Karaa ^{a, *}, Amy Goldstein ^b, Cristy Balcells ^c, Kira Mann ^c, Laura Stanley ^d, Philip E. Yeske ^e, Sumit Parikh ^f

- a Department of Genetics, Massachusetts General Hospital, Boston, MA, USA
- ^b Human Genetics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- ^c MitoAction, Boston, MA, USA
- ^d Foundation for Mitochondrial Medicine, Atlanta, GA, USA
- e United Mitochondrial Disease Foundation, Pittsburgh, PA, USA
- f Neurogenetics, Center for Pediatric Neurology, Cleveland Clinic Children's Hospital, Cleveland, OH, USA

ARTICLE INFO

Article history: Received 2 July 2019 Received in revised form 22 July 2019 Accepted 24 July 2019 Available online 30 July 2019

Keywords:
Mitochondrial disease
Health care delivery
Patients' perception of care
Physicians' opinion on care delivery

ABSTRACT

This article presents data that examine the patient's perception of health care delivery for mitochondrial disease in the US. It also presents the opinions of mitochondrial disease expert physicians about creating a specialised network of clinics to oversee the care of patients with this disease within the US. Two separate electronic surveys were developed; one for mitochondrial disease patients and their families ascertaining their satisfaction with their current health care and the challenges they face. The other for the physicians group assessing the usefulness, feasibility and readiness to develop specialized care clinics for mitochondrial disease in the US. Survey responses and descriptive analysis are presented here. The data in this article is supplemental, and supports the information presented in the research article "Harmonizing care for rare diseases: How we developed the mitochondrial care network in the United States." Karaa et al., 2019

© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

DOI of original article: https://doi.org/10.1016/j.ymgme.2019.05.012.

* Corresponding author.

E-mail address: akaraa@mgh.harvard.edu (A. Karaa).

Specifications Table

lab
ealth
ealth care delivery for rare disease.
able
lectronic survey
aw, analysed with descriptive statistics
ll data obtained from the surveys of patients and physicians was analysed.
ata was collected electronically using an email link.
ountry: Patients and physicians residing in the US
/ith the article
uthor's name: Amel Karaa, Amy Goldstein, Cristy Balcells, Kira Mann, Laura Stanley,
hilip E. Yeske, Sumit Parikh
tle: Harmonizing care for rare diseases: How we developed the mitochondrial care
etwork in the United States.
ournal: Molecular genetics and metabolism
ttps://doi.org/10.1016/j.ymgme.2019.05.012
i i i i i

Value of the Data

- This data provides a first look at the patients and physicians' perception of care delivery for primary mitochondrial disease in the US and the challenges they face.
- Health care providers and practice managers will find this data very useful in better understanding the health care gaps within their institutions.
- These data are the first step to identify the challenges and the gaps in health care delivery for mitochondrial disease in the US and will serve as road map to improve those challenges and fill those gaps [1].

1. Data

The data set presented includes survey responses from 1) patients with self-reported mitochondrial disease (MD) and their caregivers and 2) US physicians, these are physicians expert in mitochondrial diseases, practicing within the United States. Table 1 shows the 14 multiple choice and open-ended questions (left column) of the patients' survey assessing MD disease duration, relationship of patients and their families with their health care providers, communication within the health care team and limitations of care delivery. Subjects responses are summarized in the middle column of Table 1 with the number of responses (N) and the percentage of the responses to each specific question presented on the right, last 2 columns. The open-ended responses to the last question are presented in Table 2.

Table 3 represents responses to the 11 questions (left column) asked of US physicians about the importance of establishing a specific MD health care network [1]. The answers from the 44 responding physicians are presented in the middle column with the number of respondents (N) and the percentage of each specific response to each question (right columns).

2. Experimental design, materials, and methods

Information from 2 electronic survey instruments were obtained from 1) patients with mitochondrial disease (MD) and their caregivers and 2) US physicians, experts in mitochondrial diseases.

1) Patients' survey

2.1. Survey design

The survey instrument was intended for patients with MD and their family members or caregivers. A total of 14 multiple-choice and open-ended questions were developed to capture MD duration since diagnosis, relationship of patients and their families with their health care providers, communication within the health care team and limitations of care delivery. The questions were inspired by several discussions with patients and families and hearing about their concerns conveyed through MD

Table 1Patients' perspective on their mitochondrial health delivery by their care team.

Questions		N/243	%
How long ago were you or your family member first	18 months or less	33	13.6
diagnosed with mitochondrial disease?	2–5 years	83	34.1
alagnosca with intochonarial alsease.	Over 5 years	127	52.3
Which of the following best represents the most	I do not have enough time to discuss all my issues	33	13.6
significant limitation for your relationship with	with my PCP/pediatrician during the visit.	33	13.0
your primary care provider (PCP)/pediatrician?	I do not think my PCP/pediatrician understands	131	54
		151	54
(choose one)	mitochondrial disease well enough to treat me.	24	0.0
	My PCP/pediatrician is not always available to take	21	8.6
	my calls or see me.		
	My PCP/pediatrician does not feel comfortable	39	16
	dealing with my health concerns because I/my child		
	am/is too complex		
	My PCP is a pediatrician and says I/my child am/is	8	3.3
	too old for the practice, but I can't find a new adult		
	PCP to agree to take me on.		
	I do not feel I can trust my PCP/pediatrician	5	2
	I do not have a PCP.	6	2.5
How often do you see your primary care provider	Every 3 months	68	28
(PCP)/pediatrician?	Every 6 months	48	19.7
(i ci //pediatrician:	Once a year	44	18
	•		
0 19.1	Only when necessary due to illness	83	34.3
How many specialists do you or your child/family	One	16	6.6
member see for your healthcare needs?	Two	23	9.5
	Three or more	203	84
Do you or your child/family member have a	Yes	151	62
mitochondrial disease specialist?	No	58	24
	I/my child/family member had a mitochondrial	34	14
	disease specialist in the past but do not have one		
	now		
If you have a mitochondrial disease specialist,	My specialist is too busy; he/she can't see me	42	17.3
which of the following responses best represents	frequently or acutely if I get sick suddenly.		17.5
the limitation of your relationship with him/her?	My specialist is located far away from where I live; I	64	26.3
the initiation of your relationship with himpher:	can't drive/fly to see him/her as often as I would like	0-1	20.5
	to	0	3.2
	My specialist is not involved in my care when I get	8	3.2
	admitted to a hospital where he/she is not affiliated		
	to.		
	My specialist does not communicate with my PCP/	24	10
	pediatrician and other providers.		
	My PCP/pediatrician and/or other providers don't	35	14.4
	communicate with my Mito specialist.		
	I do not have a mitochondrial disease specialist.	70	28.8
Which healthcare provider do you feel is in charge	Primary care provider (PCP)/pediatrician	80	33
of you or your child/family member's healthcare	Another specialist	44	18
needs?	Mitochondrial specialist	51	21
necus.	No one	68	28
Are you satisfied that your/family member's	Yes	79	32.5
		164	
healthcare is well organized and that your	No	104	67.5
healthcare providers work together?	Nove	12	_
How often were you given confusing or	Never	12	5
contradictory information about your/family	Rarely	48	19.7
member's healthcare treatments?	Sometimes	103	42.3
member's healthcare treatments?	Frequently	80	33
		80	33
What, if any, negative impacts have the limitations	Mental health (anxiety, depression, anger)	00	
	Mental health (anxiety, depression, anger) Ability to walk/move/participate in daily activities	64	26.3
What, if any, negative impacts have the limitations			
What, if any, negative impacts have the limitations with your healthcare provider that you listed on your/your child's health? (Please choose up to 3	Ability to walk/move/participate in daily activities Sleep	64 33	13.6
What, if any, negative impacts have the limitations with your healthcare provider that you listed on	Ability to walk/move/participate in daily activities Sleep Ability to eat/digest food normally	64 33 57	26.3 13.6 23.5 45.7
What, if any, negative impacts have the limitations with your healthcare provider that you listed on your/your child's health? (Please choose up to 3	Ability to walk/move/participate in daily activities Sleep	64 33	13.6

Table 1 (continued)

Questions		N/243	%
	Interactions with other people, including classmates, teachers, community and family	17	7
	Disease progression	91	37.
	I do not feel there has been any negative health	39	16
	impact	30	
If your primary care provider (PCP)/pediatrician and mitochondrial disease specialist could communicate more efficiently together and	My PCP/pediatrician and Mito specialist would directly talk to each other every time one of them sees me so that they could go over the plan with	110	45
collaborate more actively to treat you, what	each other directly.		
would be the key changes that you would find	My PCP/pediatrician and Mito specialist would	40	16
most helpful? (Please chose up to 3 answers).	ideally see me at the same time so that a common	40	10
	plan can be made at the time of the visit.		
	My PCP/pediatrician and Mito specialist would both	94	38
	be available when I become acutely sick so that they		
	can manage me together.		
	My PCP/pediatrician and Mito specialist would both	94	38
	be involved when I get admitted to the hospital so		
	that they can be actively involved in my care.		
	I don't want to bother my Mito specialist for every	110	45
	problem. I think my PCP/pediatrician should be		
	comfortable enough to help me, but I would like the		
	option that my PCP/pediatrician can consult with		
	my Mito specialist if he/she has questions/concerns		
	I would like to see my Mito specialist more often.	45	18
f you were offered a well coordinated medical team	Mental health (anxiety, depression, anger)	83	34
involving your primary care provider (PCP)/	Ability to walk/move/participate in daily activities	73 22	30 9
pediatrician and mitochondrial disease specialist who would work together to address your	Sleep Ability to eat/digest food normally	44	18
medical needs more efficiently, what would be	Energy level	141	58
the TWO best measures of improved quality of life	Pain level	69	28
for you/your child that you would perceive as	Interactions with other people, including	33	13
most meaningful? In other words, what type of	classmates, teachers, community and family	33	
improvement would be most meaningful to you	,,,		
as a direct result of this improved coordinated			
medical care? (Please chose up to 3 answers).			

advocacy groups representatives who interact with these patients continuously and from treating physicians managing these patients in clinic.

2.2. Participants and recruitment

The survey was administered electronically through MitoAction; a MD patient advocacy group, email list server. These are self-reported MD subjects who agreed to receive news and study notifications from MitoAction. The survey was sent to 360 subjects and responses were obtained from 243 subjects (67.5% response rate) with complete answers (Supplemental Table 1).

2.3. Statistical analysis

Descriptive statistics were used. All raw data was obtained from self-response queries entered by participants.

1) Physicians' survey

2.4. Survey design

After review of the patients' survey responses, evaluation amongst the Mitochondrial Medicine Society (MMS) board members and informal discussions with several national mitochondrial disease

Table 2Selected open-ended responses from the patients' perspective survey.

Negative outcome from lack of communication and joint decision making between doctors taking care of MD patient (open ended question)

Unnecessary appointments with doctors who did not understand MD.

My MD specialist is a researcher and rarely gets involved in the management of mitochondrial disease.

Lack of continuity of care by seeing different doctors in a practice/academic center

Doctors on my team can't agree on the cause of my symptoms and no one wants to take responsibility or take ownership of my management.

Have had multiple instances of meds being prescribed by one specialist to manage specific symptoms, only to have another type of specialist tell us the med is detrimental to my son's health.

My PCP/local doctors refuse to follow the orders of my out of state MD doctor

We have more knowledge about MD than our doctors. Our frustration is that we manage the care between each of our specialists. This has been a great stress, never knowing if we are doing all that we should be for our son and what impact that is having on his progression.

It is very difficult to coordinate care by myself - I am a single parent and am trying to hold a full-time job in addition to spending hours coordinating care for my daughter.

My PCP doesn't know anything about MD so she just does what he says to do. It would be great if all PCP were trained in MD. Yes, my child has been prescribed treatments by the MD specialist that the PCP did not know about or understand. The PCP has also been forced to care for my child in ways she feels are "over her head." As a result, the PCP cannot defend care decisions for my child when other doctors ignorant of my child's needs criticize or challenge them.

It is like being in the middle of the ocean alone ... a very hopeless feeling.

It makes me feel very alone. I am forced to treat myself and hope for the best.

It has delayed care. Lack of coordinated care has resulted in it taking years to receive treatment where it should have taken weeks.

I, have been in the middle of two specialists battling over a health decision for my child on more than one occasion. It leads me to not trust one of my child's doctors, to feel I have to choose sides. It leads to much added worry and stress!

Managing my child's health is a full-time job. Walking on eggshells with unsympathetic/disinterested medical professionals while my child is in pain.

Often, I hear that we are too complex, and they try to get someone else to take on the care. However, there isn't really someone else to go to.

It has created lot of anxiety during critical times.

I see a different specialist every time I have an appointment, I have to explain my condition to them over and over as they don't know what it is, its symptoms, or how it should be treated.

As a patient, it's like being a diplomat negotiating a peace treaty between my doctors.

colleagues across the US led to the creation of a second survey. The MMS is a non-profit, physician-led organization which develops medical and clinical guidelines for the diagnosis and treatment of MD. The physician survey contained 11 multiple-choice and open-ended questions to assess the interest of US MD physicians in establishing MD care centers. The survey specifically asked about how they thought such a center would function within their own specific health care system and how differing their "wish list" for such a center would be when compared to that of the patients and their caregivers (Supplemental Table 2).

2.5. Participants and recruitment

The survey was sent by email to the MMS membership of more than 200 physicians and requested that only US physicians participate. Answers from 44 respondents was received.

2.6. Statistical analysis

Descriptive statistics were used. All raw data was obtained from self-response queries entered by participants.

Table 3Physicians' perspective on the development of a mitochondrial care expert network.

A2	Responses	N/44	%	
Do you think that centers of excellence for mitochondrial disease should be created in the US?	Yes No	41 3	93.2 6.8	
Do you think that a center of	Clinical services only	12	27.3	
excellence needs to offer:	Both clinical and research service	32	72.7	
Do you think a center of	Just children	4	9.1	
excellence needs to service	Just adults	0	0	
both children and adults?	Both clinical and research service	40	90.9	
Does a center of excellence	Yes	42	95.5	
need to provide diagnostic services and comprehensive initial evaluation for newly diagnosed patients?	No	2	4.5	
Does a center of excellence	Yes	40	93	
need to provide follow up and management of patients?	No	3	7	
Does a center of excellence	Yes	41	93.2	
need to provide Inpatient care/support as needed	No	3	6.8	
What services do you think need to be offered in a center of excellence? (Check all that	Coordinated care within the institution with access to subspecialists	44	100	
apply)	Coordinated care with outside providers	38	86.4	
	Arrangements for transitional care from children's to adults' services	37	84.1	
	Emergency Access (on call service)	35	79.5	
	Education (for patients, community, other providers)	40	90.9	
	Well defined standard of care Protocols for emergency visits, anesthesia	41	93.2	
	On Site Lab with access to biochemical and genetic testing	20	45.5	
	Access to patients registries	37	84.1	

	Access to clinical trials on site	32	72.7		
	Access to state of the art genetic	39	88.6		
	testing (as covered by the				
	patient's insurance)				
Please list any other services	Local patient support groups				
you think need to be offered	Connection to palliative care serv	rices			
at a center of excellence.	Access to social work services for	families			
	Database for all centers to keep to	rack of diagnoses and patients nationally.			
	Access to clinical trials on site				
	Multidisciplinary input (nurse, th	erapists, social worker, dietician)			
What personnel should be	Geneticist	42	95.5		
available in a center of	Neurologist	43	97.7		
excellence (Check all that	Genetic counselor	38	86.4		
apply)?	Clinical coordinator	39	88.6		
	Social worker	36	81.8		
	Nutritionist	35	79.5		
	Therapists (OT, PT, Speech)	30	68.2		
	Insurance coordinator	25	56.8		
List any other key personnel	Social worker for school advocacy	y, insurance concerns/disability			
	Family practice NP, internist, or pediatrician				
	On site ED				
	Inborn error of metabolism specia	alists (pediatricians/internal medicine) for both childrer	and adults		
	Advanced practice nurses				
	Dedicated perioperative team				
	Exercise testing/kinesiology,				
Please list the essential core of		ology, Audiology, Pulmonology with specialty in hypers	alivation/aspiration.		
specialists that need to be					
available in a center of		xpertise in ataxia, chorea/dystonia and spasticity			
excellence? (List all)	Neuroradiology, Anesthesia, GI/Motility team, Feeding team, Nutrition, Endocrinology, psychiatry,				
	maternal-fetal medicine, urology, intensivists.				
	Autonomic specialist (covered either by neurologist or cardiologist), developmental specialist				
	Biostatistical and clinical trial expertise				
	Infectious disease, Rheumatology				
What kind of well-defined	Emergency visits	43	97.7		
standard of care protocols	Anesthesia	42	95.5		
should be available through a	Surgery	33	75		
center of excellence? (Check	Sick protocol	42	95.5		
all that apply)					

(continued on next page)

Table 3 (continued)

A2	Responses	N/44	%
Please list all other protocols you think need to be available in a center of excellence	fluids/fasting status with Postpartum care, vaccine Protocols should be vett Consistent diagnostic an is not genetically confirr School related materials Dehydration, dysautono Acute stroke Supplement use Anesthesia Long distance travel Biomarker & Nutritional	ed by experts from around country a d treatment criteria used across cent ned, consistent preventative/mainter , seizure management suggestions ar mia exacerbation. monitoring	and published if possible ters; consistent labeling of patients if diagnosis nance care
Do you have any other suggestions?	I think this is a bad idea Periodic webinars or cor Rigid requirements for con A certain number of exc permitted to have cut of There is little incentive for I doubt that MMS set state Perversely, standards man Finding ways to make the Good Mito care is expen	complicated social issues . This issue will drain our energy. Iferences to teach providers who wil enters will insure that there are very eptions is needed. In particular, spec if ages of 21 or older. For institutions to provide the missing andards will result in an increase in t ay further limit access. e field economically viable is the on sive. However, society pays for ICU of also by recognized as valuable and a	

OT: Occupational therapy, PT: Physical therapy, ED: emergency department, MD: mitochondrial disorders, NP: nurse practitioner, MELAS: mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes, MMS: mitochondrial medicine society, ICU: intensive care unit, GI: gastro-enterologist.

Acknowledgments

We would like to thank all the patients and their families as well as all the mitochondrial disease physicians who have participated in these surveys.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.dib.2019.104343.

References

[1] A. Karaa, A. Goldstein, C. Balcells, K. Mann, L. Stanley, P.E. Yeske, S. Parikh, Harmonizing care for rare diseases: how we developed the mitochondrial care network in the United States, Mol. Genet. Metab. 127 (2) (2019 Jun) 122–127, https://doi.org/10.1016/j.ymgme.2019.05.012. Epub 2019 May 23.PMID: 31138493.